> ## Content Index
> Fetch the complete content index at: https://med-techinsights.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Volta Medical announces U.S. label expansion for Volta AF-Xplorer
- URL: https://med-techinsights.com/volta-medical-anounces-u-s-label-expansion-for-volta-af-xplorer/
- Published: 2025-06-12T11:43:19.000Z
- Updated: 2026-10-23T02:47:54.000Z
- Description: Volta Medical, a health technology company on a mission to treat the underserved complex atrial fibrillation (AF) patient population through the use of intelligent, AI solutions, has announced a significant update to the U.S. labelling of its flagship system, Volta AF-Xplorer. The AF-Xplorer deliver
- Author: Oliver Johnson
- Tags: Digital Health & AI, News, Artificial Intelligence

[**Volta Medical**](https://www.volta-medical.com/?ref=med-techinsights.com), a health technology company on a mission to treat the underserved complex atrial fibrillation (AF) patient population through the use of intelligent, AI solutions, has announced a significant update to the U.S. labelling of its flagship system, Volta AF-Xplorer. The AF-Xplorer delivers real-time, AI-driven insights to electrophysiologists, enabling more patient-specific decision-making in catheter ablation procedures treating AF.

Labeling will now include the groundbreaking clinical data from the landmark TAILORED-AF trial which showed significantly improved long-term outcomes in the treatment of persistent AF compared to standard-of-care. Persistent AF is among the most challenging cardiac arrhythmias and represents 3/4 of all patients suffering from AF. However, only 1/3 of catheter ablations are performed on this more progressed disease state, resigning many to live with the debilitating disease.

TAILORED-AF is a prospective, multicenter, randomised controlled trial comparing standard of care to the Volta AF-Xplorer AI-guided tailored ablation. Results are compelling: in the mITT population 88% of patients in the tailored arm were free from AF at 12 months, compared to just 70% of patients treated with standard pulmonary vein isolation (p<0.0001). The Volta AF-Xplorer is the first system in the history of electrophysiology to demonstrate level one evidence of improved efficacy outcomes for persistent AF patients. The study was published in [Nature Medicine](https://www.nature.com/articles/s41591-025-03517-w?ref=med-techinsights.com) earlier this year. 

“This label expansion is an important step for Volta Medical, and for millions of patients living with persistent AF,” said Theophile Mohr Durdez, CEO and co-founder of Volta Medical. “Clinical evidence now supports that Volta AF-Xplorer can assist physicians in improving outcomes for a vast and challenging arrhythmia population.”